XPro1595 for Alzheimer's Disease
(MINDFuL Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro1595 in patients with early ADi.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot participate if you have used cannabis in the last 6 months or have been in another clinical trial with investigational drugs within 60 days before starting this trial.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What safety data is available for XPro1595 in Alzheimer's treatment?
Is XPro1595 a promising drug for Alzheimer's Disease?
How is the drug XPro1595 different from other Alzheimer's treatments?
What data supports the idea that XPro1595 for Alzheimer's Disease is an effective drug?
The available research does not provide any data supporting the effectiveness of XPro1595 for Alzheimer's Disease. The studies mentioned focus on other treatments like ganglioside GM1, dimebon, LY2599666, and memantine, but none of these studies include XPro1595. Therefore, there is no evidence from the provided information to suggest that XPro1595 is an effective treatment for Alzheimer's Disease.311121314
Who Is on the Research Team?
Therese Blomberg
Principal Investigator
INmune Bio
Are You a Good Fit for This Trial?
This trial is for adults aged 60-85 with mild Alzheimer's Disease, confirmed by a biomarker test. Participants must be able to perform daily activities with minimal help and have a caregiver available. Those in other trials, with severe blood pressure issues, MRI contraindications, major psychiatric disorders or recent substance abuse are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 1.0 mg/kg XPro1595 or placebo via subcutaneous injection once a week
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Placebo
- XPro1595
Find a Clinic Near You
Who Is Running the Clinical Trial?
Inmune Bio, Inc.
Lead Sponsor